Literature DB >> 16622738

Tamoxifen flare hypercalcemia: an additional support for gallium nitrate usage.

Govinda Pillai Arumugam1, Sengoden Sundravel, Palanivel Shanthi, Panchanadham Sachdanandam.   

Abstract

In 12 of 93 hypercalcemic patients with metastatic advanced breast cancer treated with tamoxifen the most common life-threatening metabolic complication of flare hypercalcemia developed. All the hypercalcemic patients had osteolytic or mixed lytic and blastic bone metastases. In patients with advanced breast cancer, hypercalcemia develops within the first few weeks of initiation of tamoxifen therapy. In our study group, calcium levels were measured frequently in both serum and urine samples by a semi-autoanalyzer and an autoanalyzer, using standard methods. Elevation of calcium levels was noticed in the tamoxifen-receiving hypercalcemic breast cancer patients, and levels returned to normal when tamoxifen was withdrawn. The median duration of flare hypercalcemia was 9 days (range, 4-16 days). The median calcium value was 13.6 mg/dl (range, 11.7-15.8). The diagnosis of tamoxifen flare hypercalcemia was based on the normal pretreatment serum or urine calcium values and the occurrence of hypercalcemia within the first few weeks of tamoxifen initiation. There are no specific treatment recommendations for hormone flare hypercalcemia, except for tamoxifen withdrawal, which is usually temporary, and the introduction of a low dose of an antihypercalcemic drug. We evaluated the effect of such a drug, gallium nitrate, on flare hypercalcemia. All the patients were treated with hydration, and 6 patients, whose calcium level was above 13.6 mg/dl, were treated with a moderate dose of gallium nitrate (200 mg/m(2) per kg) for 5 consecutive days, they achieved normocalcemia and continued with tamoxifen. The median time from hormonal drug initiation to flare hypercalcemia was 17.5 days, and median duration was 9 days. The above result indicates that the serious metabolic complication of hypercalcemia develops due to the iatrogenic effect of tamoxifen, but it can be controlled with an antihypercalcemic drug, gallium nitrate, while continuing tamoxifen therapy. It seems that the use of gallium nitrate in the treatment of flare hypercalcemia could allow safe readministration of tamoxifen and prevent premature tamoxifen discontinuance or withdrawal.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16622738     DOI: 10.1007/s00774-005-0678-4

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  26 in total

1.  Hypercalcemia complicating breast cancer. Clinical features and management.

Authors:  H L Davis; A N Wiseley; G Ramirez; F J Ansfield
Journal:  Oncology       Date:  1973       Impact factor: 2.935

2.  Extended survival in advanced-stage multiple myeloma patients treated with gallium nitrate.

Authors:  Ruben Niesvizkya; C Galen Choy; David Siegel; Larry Lyons; Joseph Michaeli
Journal:  Leuk Lymphoma       Date:  2002-03

3.  Human mammary tumor growth promotion by medroxyprogesterone acetate in the tumor stem cell clonogenic assay.

Authors:  J L Bernheim; W Callewaerts; R Paridaens; C Roobol
Journal:  Cancer Treat Rep       Date:  1983-01

4.  Tamoxifen and hypercalcemia.

Authors:  J S Patterson; B J Furr; L A Battersby
Journal:  Ann Intern Med       Date:  1978-12       Impact factor: 25.391

5.  Gallium nitrate for advanced Paget disease of bone: effectiveness and dose-response analysis.

Authors:  R P Warrell; B Bosco; S Weinerman; B Levine; J Lane; R S Bockman
Journal:  Ann Intern Med       Date:  1990-12-01       Impact factor: 25.391

6.  Evaluation of tamoxifen dose in advanced breast cancer: a progress report.

Authors:  D C Tormey; R M Simon; M E Lippman; J M Bull; C E Myers
Journal:  Cancer Treat Rep       Date:  1976-10

7.  Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen.

Authors:  K B Horwitz; Y Koseki; W L McGuire
Journal:  Endocrinology       Date:  1978-11       Impact factor: 4.736

Review 8.  Skeletal complications of malignancy.

Authors:  R E Coleman
Journal:  Cancer       Date:  1997-10-15       Impact factor: 6.860

Review 9.  Gallium in cancer treatment.

Authors:  Philippe Collery; Bernhard Keppler; Claudie Madoulet; Bernard Desoize
Journal:  Crit Rev Oncol Hematol       Date:  2002-06       Impact factor: 6.312

Review 10.  Current status of endocrine therapy for metastatic breast cancer.

Authors:  G Kimmick; H B Muss
Journal:  Oncology (Williston Park)       Date:  1995-09       Impact factor: 2.990

View more
  5 in total

Review 1.  Estrogen receptor modulators and down regulators: optimal use in postmenopausal women with breast cancer.

Authors:  Christa K Baumann; Monica Castiglione-Gertsch
Journal:  Drugs       Date:  2007       Impact factor: 9.546

2.  Flare hypercalcemia after letrozole in a patient with liver metastasis from breast cancer: a case report.

Authors:  Katsumasa Kuroi; Toshinari Yamashita; Tomoyuki Aruga; Kazumi Horiguchi; Dai Kitagawa; Susumu Sekine; Hiromi Tokita; Yuka Hirashima
Journal:  J Med Case Rep       Date:  2011-10-04

3.  Letrozole induced hypercalcemia in a patient with breast cancer.

Authors:  Suleyman Hilmi Ipekci; Suleyman Baldane; Ercument Ozturk; Murat Araz; Huseyin Korkmaz; Fatih Colkesen; Levent Kebapcilar
Journal:  Case Rep Oncol Med       Date:  2014-05-15

4.  Challenges of Differential Diagnosis Between Primary Hyperparathyroidism and Bone Metastases of Breast Cancer.

Authors:  Maksym Gorobeiko; Andrii Dinets; Denys Pominchuk; Karim Abdalla; Yuriy Prylutskyy; Viktoria Hoperia
Journal:  Clin Med Insights Case Rep       Date:  2022-09-20

5.  Complementary and alternative medicine (CAM) supplements in cancer outpatients: analyses of usage and of interaction risks with cancer treatment.

Authors:  Clemens P J G Wolf; Tobias Rachow; Thomas Ernst; Andreas Hochhaus; Bijan Zomorodbakhsch; Susan Foller; Matthias Rengsberger; Michael Hartmann; Jutta Huebner
Journal:  J Cancer Res Clin Oncol       Date:  2021-07-06       Impact factor: 4.322

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.